| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680644 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2016 | 7 Pages |
Abstract
Results are compatible with design of the ongoing solanezumab EXPEDITION 3 trial that limits patients to those with mild AD dementia and evidence of amyloid pathology.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Yun-Fei Chen, Xiwen Ma, Karen Sundell, Karla Alaka, Kory Schuh, Joel Raskin, Robert A. Dean,